Molecular structure of Leflunomide, CAS Number: 75706-12-6
Leflunomide (CAS 75706-12-6)
See product citations (5)
Alternate Names:
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); HWA486; N-(4-Trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide
Application:
Leflunomide is an inhibitor of Cox-2 and tyrosine kinase
CAS Number:
75706-12-6
Purity:
≥99%
Molecular Weight:
270.20
Molecular Formula:
C12H9F3N2O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Leflunomide is an immunosuppressive drug that inhibits T and B cell responses. Leflunomide is an inhibitor of Cox-2, of tyrosine phosphorylation (tyrosine kinase), of DHODH (dihydroorotate dehydrogenase), an enzyme for de novo pyrimidine synthesis, and of TNF-dependent NF-kappaB activation. The physiological activity of leflunomide is attributed mainly to its metabolite A77 1726. By targeting the enzyme dihydroorotate dehydrogenase (DHODH), responsible for pyrimidine nucleotide synthesis, it effectively obstructs DNA and RNA production.
Leflunomide (CAS 75706-12-6) References
- Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. | Bartlett, RR., et al. 1991. Agents Actions. 32: 10-21. PMID: 2058454
- Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFκB pathway. | Elshaer, RE., et al. 2019. Life Sci. 235: 116824. PMID: 31476305
- Efficacy of leflunomide in the treatment of vasculitis. | Mustapha, N., et al. 2021. Clin Exp Rheumatol. 39 Suppl 129: 114-118. PMID: 33200732
- Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis. | Jin, R., et al. 2021. Mol Cancer Ther. 20: 274-283. PMID: 33293343
- Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses. | Huang, H., et al. 2021. Int Immunopharmacol. 93: 107434. PMID: 33556668
- Leflunomide therapy for adult patients with steroid-dependent minimal change disease or primary focal segmental glomerulosclerosis. | Zhao, C., et al. 2022. Chin Med J (Engl). 135: 866-868. PMID: 34935693
- Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat. | Bartlett, RR. and Schleyerbach, R. 1985. Int J Immunopharmacol. 7: 7-18. PMID: 3873420
- Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. | Xu, X., et al. 1995. J Biol Chem. 270: 12398-403. PMID: 7759480
- Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. | Mattar, T., et al. 1993. FEBS Lett. 334: 161-4. PMID: 8224241
- The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. | Davis, JP., et al. 1996. Biochemistry. 35: 1270-3. PMID: 8573583
- Regulation of B cell function by the immunosuppressive agent leflunomide. | Siemasko, KF., et al. 1996. Transplantation. 61: 635-42. PMID: 8610393
- Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. | Xu, X., et al. 1996. Biochem Pharmacol. 52: 527-34. PMID: 8759024
- In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. | Xu, X., et al. 1997. J Immunol. 159: 167-74. PMID: 9200452
- Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs. | Curnock, AP., et al. 1997. J Pharmacol Exp Ther. 282: 339-47. PMID: 9223572
Inhibitor of:
1600002H07Rik, 1700013F07Rik, 6330569M22Rik, 6430537H07Rik, Adenovirus hexon protein, Adenovirus-5 hexon, AdSS1, AGXT2L2, AICAR transformylase, Aminopeptidase P1, APOBEC4, ATPBD1B, ATPBD4, B7-H4, BC035044, BTN3A1, BTNL10, C14orf152, C17orf83, C19orf44, C1orf110, C1orf55, C1QDC2, C20orf142, C20orf77, C22orf29, C2orf4P, C2orf60_1110034B05Rik, C78339, C87436, C9orf97, CASD1, CD16, CD3-ζ, CMV, CMV pp52, CMV pp72, Cox-2, CTDSP1, CTGLF2, CTP Synthase (CTPS), CTPS1, CTPS2, DDX41, DHODH, DnaJC5γ, DSCR 2, FAM24A, FAM90A1, FBXW24, FLJ25371, FLJ40142, FLJ41047, GRAIL, GSC, HA-1, HDX, HLA-B27, HLA-DM, HLA-DO, HLA-DP, HLA-DQ, HLA-DR, HLA-HB1, HNF-1α, HSV-1 VP16, HSV-2 ICP10, ICF45, IFIT1L, IFN-α4, IFN-αR, IgA2, Igbp1b, IgG, IgG κ light chain, IgG2, IgG2a, IgG3, IgHg, IL-1β, IL-10, IL-6, ILT-3, IMPDH1IMPDH2, IMPDH2, Integrin αL, KHNYN, KIAA0317, KIAA0753, KIAA1712, KIR2DL1, Klra22, Leukocyte Marker, LOC100040870, LOC100041220, LOC100041339, LOC342918, LOC388284, LOC388553, LOC644695, LOC728414, Ly-49G, Ly-49N, Ly6G6d, Ly6G6e, Mengo 3DPol, METT5D1, MHC, MNSF-β, MOBP, MSL3L1, NGP1, NLE1, NPAL1, OMP, OPA1, Osgep, OTTMUSG00000010327, OTTMUSG00000015050, OTTMUSG00000017373, P4HA2, PDRG, POTE14, PPIAL4D, PPIAL4E, PRPSAP1, Rad21, RBA-2, RBMS2, Rheumatoid Factor, RNase Z1, Rnq1, RP24-329J6.5, Rpp29, RT1-Ac, SART2, Scrib, SerRS, Skint1, Skint5, Skint6, Skint8, SlfnL1, SLTM, SPANX-E, Spi13, T Cell Marker, T-cell receptor Vδ 1, T-cell receptor Vδ 2, TCR δ, TCR V γ 3, TDRD5, TIM-2, TMEM44, TNFα-IP 8, Trav12n-1, Trav6d-5, Trav8d-1, TSEN34, Tyrosine Kinase, UCK2, V1rc8, V1RH12, V1RJ3, Varicella Zoster Virus gpIII, vCCI, Vmn2r97, VpreB2, ZCCHC24, ZCCHC3, ZFR2, and ZNF254.Activator of:
Adenovirus-5 hexon, APOBEC3H, CD137L, CD74, CMV pp86, CMV UL94, CS1, CTPS2, CYP2C18, CYP7A1, DHODH, DUB2A, EBV Ea-R p85, GADD 45β, HLA-G, HSV-1 gG, HSV-1 ICP4, LIN-15A, NUFIP1, PIAS 3, RAG-1, Ribosomal Protein L29, SPPL2b, Stat4, TPN, TREML2, and VpreB.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Leflunomide, 10 mg | sc-202209 | 10 mg | $20.00 | |||
Leflunomide, 50 mg | sc-202209A | 50 mg | $81.00 |